Thermo Fisher Q3 revenue, adj profit beat estimates after new product launches

Overview

• Lab equipment supplier's Q3 revenue rose 9%, beating analyst expectations

• Adjusted EPS for Q3 grew 15%, beating analyst expectations

• Company cites growth strategy, new products, and execution as drivers of results

Outlook

• Thermo Fisher will provide updated 2026 financial guidance during its earnings call

Result Drivers

• NEW PRODUCTS - Co said Q3 results were driven by launches of new products including Orbitrap Isora mass spectrometer, EMPAD G2 electron detector, EliA CTD 13 Screen autoimmune test, and Ion 560 sequencing chip

• COMMERCIAL ENGINE - Co said it strengthened its commercial engine and deepened customer partnerships, including new initiatives with Mayo Clinic and opening an AI-Automation Innovation Center in South Korea

• EXECUTION - Co attributed results to execution enabled by its PPI Business System

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 27 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Thermo Fisher Scientific Inc. is $705.00, about 2.6% above its October 20 closing price of $687.37

• The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 19 three months ago

Reuters Recommended Reads

• Oct 20 - 3M tops Q3 adjusted EPS estimates, raises guidance

• Oct 20 - Intuitive Surgical Q3 results top estimates on higher da Vinci system placements

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)